Doctor of Philosophy

T.H.A.C Announces the Acquisition of an International Patent on Its Drug Candidate ALF-5755 For the Early Treatment of Type 2 Diabetes Mellitus and Relative to the Gut Microbiota Composition

Health, Diabetes, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, THAC, Patent, Infection, EADS, University, Peripheral neuropathy, Public sector, Roy Taylor (scientist), French Government of the Hundred Days, COVID-19, Pandemic, Ageing, Dysbiosis, Patient, ADA, Louis Pasteur, Lists of diseases, CSIS, INRA, Diabetes, Disease, CEO, Industry, Acquisition, University of Paris, Company, Growth, Microbiota, University of South Florida, Science, Global Virus Network, Human, Travancore–Cochin, Research, Obesity, Insulin, Hospital, Â, Sanofi, Insulin resistance, R, SA, Doctor of Philosophy, INSERM, Degenerative disease, Pharmaceutical industry, Management
Monday, September 27, 2021 - 4:15pm

This patent protects the drug candidate of THAC and its use for the protection of oxygen sensitive bacteria, for example in the gut microbiota.

Key Points: 
  • This patent protects the drug candidate of THAC and its use for the protection of oxygen sensitive bacteria, for example in the gut microbiota.
  • It allows to reinforce our robust patent portfolio as well as to develop a competitive oral formulation for our product.
  • With this patent, we accelerate our development, and we strengthen our competitive position on the market.
  • The dysbiosis, disequilibrium of the gut flora in humans, is characterized by complex changes in the microbiota and its various micro-organisms.

Young Children Gained Weight During The Pandemic

Linda, Health promotion, Summit Medical Group, Health education, Health information management, School, University of Michigan, Health, Kaiser Permanente, American Medical Association, Patient, Physician, MD, Caregiver, Michigan Department of Health and Human Services, Human, Behavior, University, Prevalence, JAMA, Journal, Overweight, COVID-19, Public health, Diet, Weight gain, Obesity, Doctor of Science, District, Doctor of Philosophy, RN, Animal, Medicine
Monday, September 27, 2021 - 4:00pm

PASADENA, Calif., Sept. 27, 2021 /PRNewswire/ -- A Kaiser Permanente study of nearly 200,000 children showed that children gained excess weight during the COVID-19 pandemic, especially those between 5 and 11 years old.

Key Points: 
  • PASADENA, Calif., Sept. 27, 2021 /PRNewswire/ -- A Kaiser Permanente study of nearly 200,000 children showed that children gained excess weight during the COVID-19 pandemic, especially those between 5 and 11 years old.
  • "When we compared the weight gain among children from 2019 to 2020, we found that there was more weight gained during the pandemic for youths of all ages," said the senior author, Corinna Koebnick , PhD, of the Kaiser Permanente Southern California Department of Research & Evaluation.
  • On average, 5- to-11-year-olds gained 5 extra pounds, while 16- to-17-year-olds gained 2 extra pounds.
  • The study found that during the COVID-19 pandemic there was an increase in body weight and in the prevalence of obesity, particularly for children 5 to 11 years old.

Machine Learning Tools for COVID-19 Patient Screening and Improved Lab Test Management to Be Discussed at the 2021 AACC Annual Scientific Meeting

Record, Efficiency, Patient, Medicare, Data, Hospital, Triage, Immunodeficiency, Disease, COVID-19, National Institute, FRCP, Severe acute respiratory syndrome coronavirus 2, Research, Degenerative disease, Laboratory, Doctor of Philosophy, LDS, Medical device, Pharmaceutical industry
Monday, September 27, 2021 - 3:49pm

Results from an evaluation of this algorithm, along with an artificial intelligence method that improves test utilization and reimbursement, were presented today at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.

Key Points: 
  • Results from an evaluation of this algorithm, along with an artificial intelligence method that improves test utilization and reimbursement, were presented today at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.
  • This can be difficult, however, because COVID-19 shares many symptoms with other viral infections, and the most accurate PCR-based tests for COVID-19 can take several days to yield results.
  • "Our study implies that use of the automated test ordering system LDS would be extremely helpful for providers, laboratories, and payers," said Shrestha.
  • AACC Annual Scientific Meeting registration is free for members of the media.

Novel Research Tackling Challenges in Women's Health Announced at the 2021 AACC Annual Scientific Meeting

Man, BC Children's Hospital Foundation, Protein, Health, Cervical cancer, Hospital, Cancer, Patient, Pregnancy, MD, Von Willebrand factor, Biomarker, Natural Resources, Fibrinogen, Virus, Human papillomavirus infection, University, Antibody, Knowledge, Woman, HPV, Bleeding, Tran, Research, Cone Health Women's Hospital, University of Energy and Natural Resources, Doctor of Philosophy, Papilloma, Vaccination, Vaccine, Birth control
Monday, September 27, 2021 - 3:45pm

This new test and a second study establishing accurate reference intervals for pregnant patients were presented today at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo, and could help resolve persistent challenges in healthcare and lab testing for women.

Key Points: 
  • This new test and a second study establishing accurate reference intervals for pregnant patients were presented today at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo, and could help resolve persistent challenges in healthcare and lab testing for women.
  • HPV is one of the most common sexually transmitted viruses, and research has clearly linked HPV infections to reproductive cancers in both women and men.
  • Determining how long protection from HPV lasts after vaccination could help to bolster public confidence in the vaccine and increase uptake.
  • AACC Annual Scientific Meeting registration is free for members of the media.

Registration Now Open for 2022 MDA Clinical & Scientific Conference to Showcase Cutting Edge Research Advancements and Clinical Achievements in Neuromuscular Diseases

NMD, EVP, Research, 2021 Essex County Council election, Gaylord Opryland Resort & Convention Center, MDA, Conference, Multimedia, Muscular dystrophy, National Sexual Violence Resource Center, Federation, CEO, Episcopal conference, Neuromuscular disease, Science, COVID-19, Degenerative disease, ALS, View, Drug development, Organization, Muscular Dystrophy Association, Convention center, Doctor of Philosophy, Industry, Pharmaceutical industry
Monday, September 27, 2021 - 3:00pm

NEW YORK, Sept. 27, 2021 /PRNewswire/ -- The Muscular Dystrophy Association (MDA) today announced that registration is open for the 2022 MDA Clinical & Scientific Conference being held March 13-16, 2022. After two years of pivoting to an innovative virtual event, we are pleased to convene our community of renowned researchers, clinicians, academicians, advocates, and industry leaders both in person at the Gaylord Opryland Resort and Convention Center in Nashville, Tennessee, and via live stream.

Key Points: 
  • NEW YORK, Sept. 27, 2021 /PRNewswire/ --The Muscular Dystrophy Association (MDA) today announced that registration is open for the 2022 MDA Clinical & Scientific Conference being held March 13-16, 2022.
  • The 2022 conference will explore all aspects of pre-clinical, translational, and clinical research and care across neuromuscular diseases (NMD) to support the development of better care and treatments for our community.
  • It will present concurrent clinical and translational sessions on topics highlighting:
    "This is a time of great promise and rapid advances in neuromuscular research and treatment," said Donald S. Wood, PhD, President & CEO, at MDA.
  • Research we have supported is directly linked to life-changing therapies across multiple neuromuscular diseases.

Elevar Therapeutics Announces New Appointments to Strengthen Its Senior Leadership Team

Biochemistry, Mike Hopkins (basketball), Therapy, University of Illinois at Chicago College of Dentistry, Sun Pharma, Pharmacokinetics, University, School, NDA, Toxicological Sciences, Doctor of Philosophy, Patient, Microbiology, Data management, Toxicology, Royal commission, Stomach, Ovarian cancer, Pharmacology, Paclitaxel, Leadership, Biopharmaceutical, Johns Hopkins University, Public health, Jiangsu Hengrui Medicine, European Commission, Drug development, VP, SALT, Orphan drug, DMPK, Academy, Pharmaceutical industry
Monday, September 27, 2021 - 3:00pm

These key strategic appointments will significantly strengthen our organization's drug development capabilities and clinical expertise, as we continue to build Elevar into a fully integrated biopharmaceutical company," said Maureen G. Conlan, M.D., F.A.C.P., Chief Medical Officer of Elevar Therapeutics.

Key Points: 
  • These key strategic appointments will significantly strengthen our organization's drug development capabilities and clinical expertise, as we continue to build Elevar into a fully integrated biopharmaceutical company," said Maureen G. Conlan, M.D., F.A.C.P., Chief Medical Officer of Elevar Therapeutics.
  • Robert "Bob" Faulkner, Ph.D., F.C.P., F.C.C.P.joins Elevar as VP of DMPK/clinical pharmacology from Sun Pharmaceutical Industries Ltd. (Sun Pharma) where he served as senior director of clinical pharmacology & biopharmaceutics.
  • In his new role, Bob's responsibilities will span all Elevar development programs, as well as exploratory studies to support evaluation of potential pipeline expansions.
  • joins Elevar as VP of non-clinical development from Voisin Consulting Life Sciences where he served as senior director, nonclinical and early clinical development.

Lupus Foundation of America Awards Four Grants to Early Career Scientists, Supporting Crucial Areas of Research and Growth in the Field

Lupus Foundation of America, Lupus, Journal of Investigative Medicine, Infection, Inflammation, Health, Patient, Lupus nephritis, Gary, IL-16, Kidney, CDA, Advisory Council, Scar, Growth, Government budget balance, MPH, Disease, Risk, Cognition, Research, Cell, Quality of life, Yale University, Doctor of Philosophy, Education, Rheumatology, Medicine, Pharmaceutical industry, Vaccine
Monday, September 27, 2021 - 3:00pm

WASHINGTON, Sept. 27, 2021 /PRNewswire/ --The Lupus Foundation of America is proud to announce the recipients of the 2021 Gary S. Gilkeson Career Development Award (CDA), a two-year grant focusing on critical lupus research while supporting early career scientists at the beginning of their careers, helping to ensure continued growth in the lupus research field.

Key Points: 
  • WASHINGTON, Sept. 27, 2021 /PRNewswire/ --The Lupus Foundation of America is proud to announce the recipients of the 2021 Gary S. Gilkeson Career Development Award (CDA), a two-year grant focusing on critical lupus research while supporting early career scientists at the beginning of their careers, helping to ensure continued growth in the lupus research field.
  • This year's grantees will focus their research on cognition, pediatric lupus, lupus nephritis and B-cell therapies.
  • Through a comprehensive program of research, education, and advocacy, we lead the fight to improve the quality of life for all people affected by lupus.
  • Learn more about the Lupus Foundation of America at lupus.org .

Anavex Life Sciences Announces Participation at 5th Pharma Pricing, Reimbursement & Market Access 2021

Dementia, Lists of diseases, Biotechnology, CNS, Mouse, Nature, Research, Epilepsy, The Michael J. Fox Foundation, Instagram, Annual report, Central nervous system disease, Therapy, Government budget balance, Degenerative disease, Conference, Cancer, Patient, LinkedIn, Central nervous system, Adult, Twitter, Industry, Pain, Amyloid, Drug development, Rett syndrome, Doctor of Philosophy, SEC, GLOBE, Pharmaceutical industry
Monday, September 27, 2021 - 2:30pm

This Conference will provide an overview of global pricing, market access systems and cost management techniques, as well as in-depth discussion of some of the most current trends and changes.

Key Points: 
  • This Conference will provide an overview of global pricing, market access systems and cost management techniques, as well as in-depth discussion of some of the most current trends and changes.
  • This Conference will bring together top pharmaceutical, biotechnology, and regulatory representatives under one roof that will address the key issues of the industry.
  • Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.
  • All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

IDEX Health & Science Receives the 2021 Laser Focus World Innovators Award

Partnership, NIR, Gold, Solution, SMS, Health, Method, Laser Focus World, Microfluidics, Program, LLC, Life, Laser, IH, UV, AOI, Doctor of Philosophy
Monday, September 27, 2021 - 2:30pm

ROHNERT PARK, Calif., Sept. 27, 2021 /PRNewswire-PRWeb/ --IDEX Health & Science (IH&S), the global leader in optofluidic components and subsystems, announced today that its Life Science Optics business unit has received the Laser Focus World Innovators Award for their Kola Deep Spectral Measurement System.

Key Points: 
  • ROHNERT PARK, Calif., Sept. 27, 2021 /PRNewswire-PRWeb/ --IDEX Health & Science (IH&S), the global leader in optofluidic components and subsystems, announced today that its Life Science Optics business unit has received the Laser Focus World Innovators Award for their Kola Deep Spectral Measurement System.
  • "On behalf of the Laser Focus World Innovators Awards, I would like to congratulate IDEX Health & Science on their Gold level honoree status," said Laser Focus Word Publisher Paul Andrews.
  • "This competitive program allows Laser Focus World to celebrate and recognize the most innovative products impacting the photonics community this year."
  • At IDEX Health & Science we believe partnership will change the way the world innovates, leading to new technologies that improve our health, protect our planet, and enrich our lives.

RaySecur Launches the MailSecur 500 High-Resolution mmWave Mail and Package Scanner for Demanding Security Imaging Applications

Government, 500, Global, Safety, Radiation, EOD, GSX, Solution, Doctor of Philosophy, Account-based marketing, Bureau, DHS, High-pass filter, Ricin, X-ray, Tobacco, CEO, ATF, Gaps, Communication, Smoke, United States Department of Homeland Security, USPIS, United States Postal Inspection Service, Powder, AstraZeneca, 3D, Weapon, QATT, HVAC, Fortune 500, Anthrax, Department, Bureau of Alcohol, Tobacco, Firearms and Explosives, Firearm, 300X, Medical imaging, Cryptocurrency, Risk management
Monday, September 27, 2021 - 2:00pm

The MailSecur 500 offers 2X the resolution of its counterpart, MailSecur 300, when "seeing inside" of objects through dynamic mmWave imaging for more precise and detailed threat detection.

Key Points: 
  • The MailSecur 500 offers 2X the resolution of its counterpart, MailSecur 300, when "seeing inside" of objects through dynamic mmWave imaging for more precise and detailed threat detection.
  • MailSecur 's screening technology intercepts and detects mail and package threats including explosives, liquids, powder, weapons, radiation, and other suspicious contents.
  • The MailSecur 500 and MailSecur 300 can also integrate within CCURE, Johnson Controls innovative building security management platform.
  • RaySecur and MailSecur are trademarks of RaySecur, Inc. For more information on RaySecur and MailSecur, visit www.RaySecur.com .